H.C. Wainwright & Co

Biopharma company developing next-generation mental health treatments Bright Minds Biosciences Inc. (NASDAQ: DRUG) has closed its overnight offering for gross proceeds of approximately $4 million. The company also announced it will start dosing patients in the trial of...

Aptose Biosciences Inc (NASDAQ: APTO) is seeing a strong run in pre-market trading Thursday following H.C. Wainwright & Co's upgrade. The firm premised its opinion change on its belief that an inflection point may be drawing near. As such, the firm upgraded shares of Aptose from Neutral to...

The first Phase 3 trials for Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL)'s Syk inhibitor are expected to be announced in August as many investors and analysts prepare for the results. H.C. Wrainwright's Positive Take On Phase 3 H.C. Wainwright & Co's Shaunak Deepak initiated Rigel...